Management of direct-acting antiviral agent failures
M Buti, M Riveiro-Barciela, R Esteban - Journal of Hepatology, 2015 - Elsevier
Failure to respond to the approved combinations of multiple direct-acting antiviral agents is
relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7 …
relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7 …
Prevention and management of treatment failure to new oral hepatitis C drugs
L Benítez-Gutiérrez, P Barreiro, P Labarga… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Chronic hepatitis C virus (HCV) infection has become a curable disease.
Sustained virologic response rates above 90% have been achieved with recommended …
Sustained virologic response rates above 90% have been achieved with recommended …
[HTML][HTML] Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Background & Aims Direct-acting antiviral (DAA) regimens provide a cure in> 95% of
patients with chronic HCV infection. However, in some patients in whom therapy fails …
patients with chronic HCV infection. However, in some patients in whom therapy fails …
The effect of multistrain probiotics on functional constipation in the elderly: A randomized controlled trial
Background and objectives Constipation is one of the most common gastrointestinal
conditions, particularly among older individuals. This study aimed to evaluate the efficacy …
conditions, particularly among older individuals. This study aimed to evaluate the efficacy …
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and …
P Krishnan, R Tripathi, G Schnell… - Antimicrobial agents …, 2015 - Am Soc Microbiol
ABSTRACT AVIATOR, a phase 2 clinical trial, evaluated ritonavir-boosted paritaprevir (a
protease inhibitor), ombitasvir (an NS5A inhibitor), and dasabuvir (a nonnucleoside …
protease inhibitor), ombitasvir (an NS5A inhibitor), and dasabuvir (a nonnucleoside …
Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of …
There is no comprehensive study available on the natural hepatitis C virus (HCV)
polymorphism in sites associated with resistance including all viral genotypes which may …
polymorphism in sites associated with resistance including all viral genotypes which may …
Resistance of hepatitis C virus to inhibitors: complexity and clinical implications
Selection of inhibitor-resistant viral mutants is universal for viruses that display quasi-
species dynamics, and hepatitis C virus (HCV) is no exception. Here we review recent …
species dynamics, and hepatitis C virus (HCV) is no exception. Here we review recent …
Resistance to DAAs: when to look and when it matters
DL Wyles - Current HIV/AIDS Reports, 2017 - Springer
Abstract Purpose of Review This review provides an overview of HCV resistance-associated
substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment …
substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment …
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors
A De Luca, S Di Giambenedetto… - Open forum …, 2015 - academic.oup.com
Abstract Background. Hepatitis C virus (HCV) genotype 1 is the most prevalent worldwide.
Subtype 1a, compared with 1b, shows lower response rates and higher propensity to select …
Subtype 1a, compared with 1b, shows lower response rates and higher propensity to select …
[HTML][HTML] Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
M Jiménez-Pérez, R González-Grande… - World Journal of …, 2016 - ncbi.nlm.nih.gov
The use of direct-acting antivirals (DAAs) to treat chronic hepatitis C has resulted in a
significant increase in rates of sustained viral response (around 90%-95%) as compared …
significant increase in rates of sustained viral response (around 90%-95%) as compared …